Evidence map›Paper›PMID 36905489›Full record

ArticleArchives of pharmacal research2023

Engineered fibrotic liver-targeted truncated transforming growth factor β receptor type II variant for superior anti-liver fibrosis therapy.

Manman Ma, Xiaohua Wang, Xiaohui Liu, Yang Han, Yanhui Chu, Yanzhong Guan, Haifeng Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of pharmacal research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Manman Ma *Heilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Xiaohua Wang *Laboratory of Pathogenic Microbiology and Immunology, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Xiaohui LiuHeilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Yang HanThe First Clinical College, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Yanhui ChuHeilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China.
Yanzhong GuanDepartment of Physiology and Neurobiology, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China. guanyan@hotmail.com.
Haifeng LiuHeilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang, 157011, People's Republic of China. fenghailiu510@163.com.ORCID http://orcid.org/0000-0003-1075-9064
Mudanjiang Medical University · CN

Funding

Central Finance supports Local Colleges and Universities Talent Development Funding from Heilongjiang Provincial Department of Finance 2020GSP09National Natural Sciences Foundation of China 81500471National Natural Sciences Foundation of China 81700544Nature Science Foundation of Heilongjiang Province for Outstanding Youth YQ2019H033
6 · The paper itself

Abstract

Truncated transforming growth factor β receptor type II (tTβRII) is a promising anti-liver fibrotic candidate because it serves as a trap for binding excessive TGF-β1 by means of competing with wild type TβRII (wtTβRII). However, the widespread application of tTβRII for the treatment of liver fibrosis has been limited by its poor fibrotic liver-homing capacity. Herein, we designed a novel tTβRII variant Z-tTβRII by fusing the platelet-derived growth factor β receptor (PDGFβR)-specific affibody Z

Indexed as

Liver CirrhosisTransforming Growth Factor beta1AnimalsCarbon TetrachlorideHepatic Stellate CellsMiceOrganic ChemicalsSignal TransductionTransforming Growth Factor betaCarbon TetrachlorideOrganic ChemicalsTransforming Growth Factor betaTransforming Growth Factor beta1Liver fibrosisPlatelet-derived growth factor β receptorTransforming growth factor β1Transforming growth factor β receptor type II

Identifiers

PMID36905489
OpenAlexW4323920700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.